BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 11013272)

  • 1. Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy.
    Schmidt M; Hochhaus A; König-Merediz SA; Brendel C; Proba J; Hoppe GJ; Wittig B; Ehninger G; Hehlmann R; Neubauer A
    J Clin Oncol; 2000 Oct; 18(19):3331-8. PubMed ID: 11013272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha.
    Reuben JM; Lee BN; Johnson H; Fritsche H; Kantarjian HM; Talpaz M
    Clin Cancer Res; 2000 May; 6(5):1671-7. PubMed ID: 10815885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha.
    Schmidt M; Hochhaus A; Nitsche A; Hehlmann R; Neubauer A
    Blood; 2001 Jun; 97(11):3648-50. PubMed ID: 11369663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of multiple myeloma oncogene 1/interferon-regulatory factor 4 gene expression in malignant B-cell proliferations and normal leukocytes.
    Yamada M; Asanuma K; Kobayashi D; Moriai R; Yajima T; Yagihashi A; Yamamori S; Watanabe N
    Anticancer Res; 2001; 21(1B):633-8. PubMed ID: 11299818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia.
    Aswald JM; Lipton JH; Aswald S; Messner HA
    Cytokines Cell Mol Ther; 2002; 7(4):143-9. PubMed ID: 14660054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients.
    Pane F; Mostarda I; Selleri C; Salzano R; Raiola AM; Luciano L; Saglio G; Rotoli B; Salvatore F
    Blood; 1999 Oct; 94(7):2200-7. PubMed ID: 10498589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Monitoring of the therapeutic response of interferon to chronic myeloid leukemia by duel-color fluorescence in situ hybridization].
    Song YQ; Li W; Kong LH; Wang GJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):38-40. PubMed ID: 12667287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-selectin expression is low on CD34+ cells from patients with chronic myeloid leukemia and interferon-a up-regulates this expression.
    Martín-Henao GA; Quiroga R; Sureda A; González JR; Moreno V; García J
    Haematologica; 2000 Feb; 85(2):139-46. PubMed ID: 10681720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic myeloid leukemia cells resistant to interferon-alpha lack STAT1 expression.
    Landolfo S; Guarini A; Riera L; Gariglio M; Gribaudo G; Cignetti A; Cordone I; Montefusco E; Mandelli F; Foa R
    Hematol J; 2000; 1(1):7-14. PubMed ID: 11920164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of interferon-alpha (IFN-alpha) receptor 2c at diagnosis is associated with cytogenetic response in IFN-alpha-treated chronic myeloid leukemia.
    Barthe C; Mahon FX; Gharbi MJ; Fabères C; Bilhou-Nabéra C; Hochhaus A; Reiffers J; Marit G
    Blood; 2001 Jun; 97(11):3568-73. PubMed ID: 11369652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular cytokine analysis of interferon-gamma in T cells of patients with chronic myeloid leukemia.
    Aswald JM; Lipton JH; Messner HA
    Cytokines Cell Mol Ther; 2002 Dec; 7(2):75-82. PubMed ID: 12607798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
    Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
    Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
    Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
    J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of cytogenetic response in Ph+ chronic myeloid leukemia patients treated with interferon alpha].
    Hong H; Qiu JY; Lai YY; Shi Y; He Q; Dang H; Lu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):269-73. PubMed ID: 12844411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia.
    Chen X; Regn S; Raffegerst S; Kolb HJ; Roskrow M
    Br J Haematol; 2000 Nov; 111(2):596-607. PubMed ID: 11122108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon alpha in the treatment of chronic myelogenous leukemia.
    Robak T
    Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Occurrence of autoimmune complications in patients with chronic myelocytic leukemia during treatment with interferon alfa].
    Tóthová E; Stecová N; Kafková A; Fricová M; Svorcová E
    Vnitr Lek; 2002 May; 48(5):380-3. PubMed ID: 12061203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.